Cargando…

Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study

BACKGROUND: Three botulinum neurotoxin type A preparations (incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA) are widely approved in Europe and in the US for the treatment of glabellar frown lines. The purpose of this study was to determine and compare the time to onset and duration o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rappl, Thomas, Parvizi, Daryousch, Friedl, Herwig, Wiedner, Maria, May, Simone, Kranzelbinder, Bettina, Wurzer, Paul, Hellbom, Bengt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789632/ https://www.ncbi.nlm.nih.gov/pubmed/24098087 http://dx.doi.org/10.2147/CCID.S41537

Ejemplares similares

AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2018)

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
por: Prager, Welf
Publicado: (2013)

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2019)

OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review
por: Dashtipour, Khashayar, et al.
Publicado: (2015)

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
por: Prager, Welf, et al.
Publicado: (2013)

IncobotulinumtoxinA for Glabellar Frown Lines in Chinese Subjects: A Randomized, Double-blind, Active-Controlled Phase-3 Study
por: Wu, Yan, et al.
Publicado: (2023)

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia
por: Misra, V. P., et al.
Publicado: (2020)

Correction to: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia
por: Misra, V. P., et al.
Publicado: (2020)

A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment
por: Trosch, Richard M., et al.
Publicado: (2015)

Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats
por: Feng, Ya, et al.
Publicado: (2017)

Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II
por: Kent, Ruth, et al.
Publicado: (2021)

Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids
por: Kassir, Ramtin, et al.
Publicado: (2013)

OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays
por: Rupp, David, et al.
Publicado: (2020)

AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol
por: Esquenazi, Alberto, et al.
Publicado: (2021)

Real-World Six-Year National Cost-Minimization Analysis of IncobotulinumtoxinA and OnabotulinumtoxinA in the VA/DoD Healthcare Systems
por: Kazerooni, Rashid, et al.
Publicado: (2021)

Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Jean, et al.
Publicado: (2023)

A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines
por: Schlessinger, Joel, et al.
Publicado: (2021)

A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines
por: Punga, Anna Rostedt, et al.
Publicado: (2016)

Subject satisfaction and psychological well‐being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines
por: Dayan, Steven, et al.
Publicado: (2022)

The Practical Use of AbobotulinumtoxinA in Aesthetics
por: Kane, Michael A. C., et al.
Publicado: (2017)

New Uses of AbobotulinumtoxinA in Aesthetics
por: Schlessinger, Joel, et al.
Publicado: (2017)

Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles
por: Carruthers, Alastair, et al.
Publicado: (2016)

Profile of Xeomin(®) (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park, Juwan, et al.
Publicado: (2011)

AbobotulinumtoxinA: A 25-Year History
por: Monheit, Gary D., et al.
Publicado: (2017)

Anatomical Proposal for Botulinum Neurotoxin Injection for Glabellar Frown Lines
por: Yi, Kyu-Ho, et al.
Publicado: (2022)

Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment
por: Hilton, Said, et al.
Publicado: (2022)

Introduction to the Supplement: A Review of AbobotulinumtoxinA (Dysport)
por: Dover, Jeffrey S.
Publicado: (2017)

Anatomical Injection Guidelines for Glabellar Frown Lines Based on Ultrasonographic Evaluation
por: Kim, Soo-Bin, et al.
Publicado: (2021)

Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport(®)/Azzalure(®)): Primary Results of the APPEAL Noninterventional Study
por: Gubanova, Elena, et al.
Publicado: (2018)

IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations
por: Yutskovskaya, Yana, et al.
Publicado: (2015)

Effects of repeated abobotulinumtoxinA injections in upper limb spasticity
por: Gracies, Jean‐Michel, et al.
Publicado: (2017)

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration
por: Nestor, Mark, et al.
Publicado: (2017)

Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study
por: Wu, Yan, et al.
Publicado: (2022)

Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial
por: Ascher, Benjamin, et al.
Publicado: (2020)

Correction: Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study
por: Wu, Yan, et al.
Publicado: (2023)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
por: Truong, Daniel D., et al.
Publicado: (2013)

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders
por: Jost, Wolfgang H, et al.
Publicado: (2015)

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato, Andrea
Publicado: (2016)

Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI
por: Berweck, Steffen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iecrnl1cki93j8kn1o66ribdha